Israel China Biotechnology (ICB) Ltd
Silver Castle Holdings Ltd operates as a healthcare investment company. It invests in companies in the biomedical field in Israel. The company was formerly known as Israel China Biotechnology (ICB) Ltd and changed its name to Silver Castle Holdings Ltd in February 2022. Silver Castle Holdings Ltd was founded in 2000 and is based in Tel Aviv, Israel.
Israel China Biotechnology (ICB) Ltd (ICB) - Total Liabilities
Latest total liabilities as of June 2021: ILA4.11 Million ILA
Based on the latest financial reports, Israel China Biotechnology (ICB) Ltd (ICB) has total liabilities worth ILA4.11 Million ILA as of June 2021.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Israel China Biotechnology (ICB) Ltd - Total Liabilities Trend (2015–2020)
This chart illustrates how Israel China Biotechnology (ICB) Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Israel China Biotechnology (ICB) Ltd Competitors by Total Liabilities
The table below lists competitors of Israel China Biotechnology (ICB) Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UBuyHoldings Inc
PINK:UBYH
|
USA | $80.78K |
|
AS Harju Elekter
STU:HD8
|
Germany | €70.26 Million |
|
Hollywood Bowl Group PLC
LSE:BOWL
|
UK | GBX287.93 Million |
|
Rank Group PLC
LSE:RNK
|
UK | GBX440.00 Million |
|
INFORMATION SVC GRP
BE:ZZG
|
Germany | €139.80 Million |
Liability Composition Analysis (2015–2020)
This chart breaks down Israel China Biotechnology (ICB) Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Israel China Biotechnology (ICB) Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Israel China Biotechnology (ICB) Ltd (2015–2020)
The table below shows the annual total liabilities of Israel China Biotechnology (ICB) Ltd from 2015 to 2020.
| Year | Total Liabilities | Change |
|---|---|---|
| 2020-12-31 | ILA7.87 Million | -18.65% |
| 2019-12-31 | ILA9.68 Million | +293.10% |
| 2018-12-31 | ILA2.46 Million | -14.16% |
| 2017-12-31 | ILA2.87 Million | +33.33% |
| 2016-12-31 | ILA2.15 Million | -10.11% |
| 2015-12-31 | ILA2.39 Million | -- |